Fresenius Kabi sales increase in first quarter of 2010

Fresenius Kabi has enjoyed a strong first quarter of 2010, with sales increasing by 11 per cent compared to the opening three months of last year.

According to the Fresenius group’s quarterly financial report, the generic drug and infusion therapy specialist recorded a sales total of 800 million euros (684.6 million pounds), of which 409 million euros came from European markets.

This total was underpinned by a nine per cent organic sales growth, while Fresenius Kabi also saw increases in its earnings and net income.

Across the group as a whole, sales reached a total of 3.6 billion euros for the quarter, leading Fresenius to state that all of its business segments are currently “on track” to meet their full year targets.

Ulf Mark Schneider, chief executive officer of Fresenius, said: “Our first quarter results give us full confidence in confirming our outlook for 2010. We expect group net income to be at the upper end of our guidance.”

This comes after the Fresenius group achieved record results during 2009, either meeting or exceeding all of its yearly financial targets in the process.